BIOMAT Database Logo BIOMAT Database Logo

Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. 1999

E Mansouri, and J Gabelsberger, and B Knapp, and E Hundt, and U Lenz, and K D Hungerer, and H E Gilleland, and J Staczek, and H Domdey, and B U von Specht
Chirurgische Universitätsklinik der Universität Freiburg, Freiburg, Germany.

A hybrid protein [Met-Ala-(His)6OprF190-342-OprI21-83] consisting of the mature outer membrane protein I (OprI) and amino acids 190 to 342 of OprF of Pseudomonas aeruginosa was expressed in Escherichia coli and purified by Ni2+ chelate-affinity chromatography. After safety and pyrogenicity evaluations in animals, four groups of eight adult human volunteers were vaccinated intramuscularly three times at 4-week intervals and revaccinated 6 months later with either 500, 100, 50, or 20 microg of OprF-OprI adsorbed onto A1(OH)3. All vaccinations were well tolerated. After the first vaccination, a significant rise of antibody titers against P. aeruginosa OprF and OprI was measured in volunteers receiving the 100- or the 500-microg dose. After the second vaccination, significant antibody titers were measured for all groups. Elevated antibody titers against OprF and OprI could still be measured 6 months after the third vaccination. The capacity of the elicited antibodies to promote complement binding and opsonization could be demonstrated by a C1q-binding assay and by the in vitro opsonophagocytic uptake of P. aeruginosa bacteria. These data support the continued development of an OprF-OprI vaccine for use in humans.

UI MeSH Term Description Entries
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008297 Male Males
D010587 Phagocytosis The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (PHAGOCYTES). Phagocytoses
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000907 Antibodies, Bacterial Immunoglobulins produced in a response to BACTERIAL ANTIGENS. Bacterial Antibodies
D001426 Bacterial Proteins Proteins found in any species of bacterium. Bacterial Gene Products,Bacterial Gene Proteins,Gene Products, Bacterial,Bacterial Gene Product,Bacterial Gene Protein,Bacterial Protein,Gene Product, Bacterial,Gene Protein, Bacterial,Gene Proteins, Bacterial,Protein, Bacterial,Proteins, Bacterial

Related Publications

E Mansouri, and J Gabelsberger, and B Knapp, and E Hundt, and U Lenz, and K D Hungerer, and H E Gilleland, and J Staczek, and H Domdey, and B U von Specht
Safety and immunogenicity of a Pseudomonas aeruginosa outer membrane protein I vaccine in human volunteers.
August 1996, Vaccine,
E Mansouri, and J Gabelsberger, and B Knapp, and E Hundt, and U Lenz, and K D Hungerer, and H E Gilleland, and J Staczek, and H Domdey, and B U von Specht
A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.
January 2014, Human vaccines & immunotherapeutics,
E Mansouri, and J Gabelsberger, and B Knapp, and E Hundt, and U Lenz, and K D Hungerer, and H E Gilleland, and J Staczek, and H Domdey, and B U von Specht
The Pseudomonas aeruginosa outer membrane protein I vaccine: immunogenicity and safe administration in man.
February 1997, Behring Institute Mitteilungen,
E Mansouri, and J Gabelsberger, and B Knapp, and E Hundt, and U Lenz, and K D Hungerer, and H E Gilleland, and J Staczek, and H Domdey, and B U von Specht
Human immune response to a Pseudomonas aeruginosa outer membrane protein vaccine.
January 1999, Vaccine,
E Mansouri, and J Gabelsberger, and B Knapp, and E Hundt, and U Lenz, and K D Hungerer, and H E Gilleland, and J Staczek, and H Domdey, and B U von Specht
Recombinant protein composed of Pseudomonas exotoxin A, outer membrane proteins I and F as vaccine against P. aeruginosa infection.
October 1999, Applied microbiology and biotechnology,
E Mansouri, and J Gabelsberger, and B Knapp, and E Hundt, and U Lenz, and K D Hungerer, and H E Gilleland, and J Staczek, and H Domdey, and B U von Specht
Tolerability and immunogenicity of a polyvalent Pseudomonas aeruginosa extract vaccine in human volunteers.
May 1988, Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology,
E Mansouri, and J Gabelsberger, and B Knapp, and E Hundt, and U Lenz, and K D Hungerer, and H E Gilleland, and J Staczek, and H Domdey, and B U von Specht
A hybrid outer membrane protein antigen for vaccination against Pseudomonas aeruginosa.
February 1997, Behring Institute Mitteilungen,
E Mansouri, and J Gabelsberger, and B Knapp, and E Hundt, and U Lenz, and K D Hungerer, and H E Gilleland, and J Staczek, and H Domdey, and B U von Specht
Structural and biological insights into outer membrane protein lipotoxin F of Pseudomonas aeruginosa: Implications for vaccine application.
December 2023, International journal of biological macromolecules,
E Mansouri, and J Gabelsberger, and B Knapp, and E Hundt, and U Lenz, and K D Hungerer, and H E Gilleland, and J Staczek, and H Domdey, and B U von Specht
Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice.
April 1984, Infection and immunity,
E Mansouri, and J Gabelsberger, and B Knapp, and E Hundt, and U Lenz, and K D Hungerer, and H E Gilleland, and J Staczek, and H Domdey, and B U von Specht
A toluene-tolerant mutant of Pseudomonas aeruginosa lacking the outer membrane protein F.
December 1995, Bioscience, biotechnology, and biochemistry,
Copied contents to your clipboard!